US Bancorp’s Artiva Biotherapeutics ARTV Stock Holding History

US Bancorp’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28K	Buy	+235	New	+$2.14K	﹤0.01%	3851

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

US Bancorp's ARTV Position: Q2 2026 in Review

US Bancorp opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 235 shares worth $2.28K. The stake represents ﹤0.01% of the portfolio and ranks #3851 among its holdings.

72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

US Bancorp held 235 shares of Artiva Biotherapeutics worth $2.28K as of Q2 2026.
Artiva Biotherapeutics was a new US Bancorp position in Q2 2026.
Artiva Biotherapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3851 holding.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.